Has results × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Peripheral Blood Stem Cell Transplantation × Clear all Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Phase 2 Completed
62 enrolled 15 charts
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Phase 1/2 Completed
54 enrolled 18 charts
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
Phase 1/2 Completed
63 enrolled 16 charts
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Phase 2 Completed
25 enrolled 10 charts
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
Phase 2 Completed
28 enrolled 10 charts
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Phase 2 Completed
47 enrolled 18 charts
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Completed
210 enrolled 15 charts
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase 3 Completed
174 enrolled 12 charts
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
Phase 2 Completed
42 enrolled 13 charts
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
Phase 2 Completed
50 enrolled 12 charts
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
Phase 2 Terminated
42 enrolled 8 charts